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Objective. We sought to compare positive surgical margin rates (PSM), estimated blood loss (EBL), and quality of life outcomes
(QOL)amongperineal (RPP),retropubic(RRP),androbot-assistedlaparoscopic (RALP)prostatectomies.Methods.Records from
463 consecutive men undergoing RPP (92), RRP (180), or RALP (191) for clinically localized prostate cancer were retrospectively
reviewed. Age, percent tumor volume, Gleason score, stage, EBL, PSM, and QOL using the expanded prostate cancer index
composite (EPIC) were compared. Results. PSM were similar when adjusted for stage, grade, and volume. EBL was signiﬁcantly
less in the RALP (189ml) group compared to both RPP (475ml) and RRP (999ml) groups. When corrected for nerve sparing,
there were no diﬀerences in erectile function and sexual function amongst the three groups. Urinary summary and pad usage
scores showed no signiﬁcant diﬀerences. Conclusion.R P P ,R R P ,a n dR A L Po ﬀer similar surgical and QOL outcomes. RALP and
RPP demonstrate less EBL compared to RRP.
1.Introduction
Radical prostatectomy remains the most commonly used
treatment for clinically localized prostate cancer and can be
performed by a variety of techniques. First performed by
Young in 1904, the radical perineal prostatectomy (RPP)
has been a proven technique for over 100 years. However,
in the early 1980s, modiﬁcations to the radical retropubic
prostatectomy (RRP) were introduced. RRP became the
most popular surgical option and gained wider acceptance
with the introduction of the nerve sparing technique by
Walsh [1]. Large series comparing RRP with RPP have
generally shown similar outcomes, except decreased blood
loss associated with RPP [2, 3]. In more recent years, robot-
assisted laparoscopic prostatectomy (RALP) and laparo-
scopic radical prostatectomy (LRP) have been introduced
as minimally invasive techniques with associated beneﬁts of
shorter recovery periods, decreased postoperative pain, and
smaller incisions [4].
There are multiple studies which have compared surgical
outcomes between the diﬀerent techniques including rates of
positive surgical margin (PSM) among the diﬀerent surgical
modalities. Several studies have shown decreased PSM rates
with RALP compared to RRP, yet others have demonstrated
no advantage when RALP is used [5–8]. Regardless of their
ﬁndings, these studies many times have inherent limitations
introduced when data from multiple surgeons is compiled.
This also creates potential bias in patient selection between
the diﬀerent surgical modalities which may impact results.
Also, the popularity of RPP has been cyclical in nature
since the introduction of RRP and RALP [2], a trend
which may further complicate direct comparisons of the
techniques. Although its eﬀectiveness compared to RRP has
beendemonstrated,thereisapaucityofdatacomparingRPP
to RALP. In addition, there is lack of data comparing QOL
outcomes between these groups. The purpose of our study
was to evaluate the incidence and location of PSM among
RPP, RRP, and RALP in 463 consecutive patients performed2 Prostate Cancer
byasinglesurgeon(JBT)atoneinstitutionfromMarch2005
to February 2009 while controlling for diﬀerences in tumor
biology, clinical, and pathological staging. We further sought
to compare QOL outcomes between these groups using the
EPIC questionnaire [9].
2.MaterialsandMethods
After exclusion of men receiving adjuvant therapy or under-
going salvage prostatectomy, the records of 463 men treated
for clinically localized prostate cancer with RPP, RRP, and
RALP from March 2005 to February 2009 were retrospec-
tivelyreviewed.Allradicalprostatectomies(92RPP,180RRP,
and 191 RALP) were performed by a single surgeon (JBT)
at one institution. All three surgeries were performed using
standard techniques that have been previously described [3,
10, 11]. The decision of technique was made by the surgeon
after thorough counseling with the patient regarding the
risks and beneﬁts of each procedure as well as both patient
and tumor characteristics. RPP was favored in patients with
morbid obesity, intra-abdominal mesh, renal transplant, or
history of extensive abdominal or intraperitoneal surgeries.
Otherwise, a discussion was undertaken with the patient
wherebothRRPandRALPwereoﬀered.RALPwasdescribed
to the patient as having the advantage of decreased EBL and
earlier hospital discharge.
Patient age, preoperative PSA level, Gleason score, ﬁnal
pathologic stage, percent tumor volume, risk classiﬁcation,
and PSM status were recorded. All pathologic specimens
were reviewed by a single uropathologist (OWT) at one
institution at the time of surgery. Percent tumor volume,
PSM status and location, and pathological stage were noted
based on the 1997 TNM classiﬁcation [12]. PSM was deﬁned
as tumor present at the inked margin of the surgically
resected prostate. PSM were classiﬁed based on their loca-
tion: anterior, apical, posterolateral, and the bladder neck.
Preoperative PSA, biopsy Gleason score, and 2002 AJCC
clinical T-category were used to stratify groups by risk
classiﬁcation according to 2007 AUA Guidelines.
EPIC questionnaires were obtained from the patients at
all follow-up intervals. For the purpose of this study, ques-
tionnaires obtained between 12–18 months postoperatively
were assessed. Complete and evaluable data were available
on 177 patients, 35(38%) RPP, 46(26%) RRP, and 96(50%)
RALP.
Statistical analysis was performed using SPSS 16 software
(Chicago, IL). The means of parametric data were compared
using t-test/ANOVA. Nominal data was examined using
Chi-squared tests. P values of .05 or less were considered
statistically signiﬁcant.
3. Results
Clinicopathologic variables including EBL and length of stay
were gathered for the patients and results are shown in
Table 1.PreoperativePSA(ng/ml)was5.64intheRPPgroup,
8.89 in the RRP group, and 6.67 in the RALP group (P =
.001). When grouped by Gleason sum, RALP cases were
more likely to be Gleason sum ≤6 at 47.6% versus 28.3%
for RPP and 21.1% for RRP (P = .013). When Gleason
sum was 8 or greater, RPP and RRP were over four times
more likely to be performed compared to RALP (P<. 001).
Patients undergoing RALP were more likely to have low-
risk disease (44.5%) versus RPP (26.1%) and RRP (20.6%)
patients. Patients with high-risk disease were approximately
three times more likely to undergo RRP or RPP compared
to RALP. Average percent tumor volumes were smallest in
the RALP group (14.8%) compared to RPP (17.7%) and
RRP (18%) groups (P<. 001). Percent tumor volumes were
then arbitrarily classiﬁed into groups of less than 10%, 10.1–
20%,20.1–30%,andgreaterthan30%.ThenumberofRALP
procedures performed was inversely proportional to percent
tumor volume.
Overall, PSM occurred in 21.4% of RPP, 28.9% of RRP,
and 13.6% of RALP (P = .007). As shown in Table 3,P S M
incidencewaslowestinlow-riskpatientsundergoingallthree
modalities. Interestingly, high-risk patients were three times
more likely to have PSM when undergoing RRP compared
to those undergoing RALP (50% versus 15.4%), and twice
as likely when undergoing RPP versus RALP. PSM rates in
patients with T2 disease were 18%, 18%, and 11% for RPP,
RRP, and RALP, respectively (P = .18). PSM rates in patients
with T3 disease were 38%, 60%, and 37% for RPP, RRP, and
RALP, respectively (P = .13).
PSM incidence rates based on percent tumor volume
for each approach are shown in Table 2.A v e r a g ep e r c e n t
tumor volume in PSM patients were similar among the
diﬀerent surgical approaches (24.1% in RPP, 26.7% in RRP,
and 24.6% in RALP; P = .98). When grouped according to
percent tumor volume, no statistically signiﬁcant advantage
was observed among the three modalities. Average EBL(ml)
was 189 for RALP, 475 for RPP, and 999 for RRP (P<. 001).
EBL did not correlate with PSM incidence in any of the
groups.
IncidenceofPSMbymarginlocationisshowninTable 4.
Locations were classiﬁed as anterior, apex, bladder neck, or
posterolateral. A few cases in each group contained more
than one site of tumor involvement. In all three groups, the
posterolateral margin was the most common site of tumor
involvement. As expected, incidence of anterior margin
involvement was highest in the RPP group (28.6%) com-
pared to RRP (17.3%) and RALP (3.8%) groups. There was a
trend for the RALP group having the smallest proportion of
PSMatthebladderneckmarginwhencomparedtotheother
2techniques,althoughthisdiﬀerencedidnotreachstatistical
signiﬁcance.
QOL scores are summarized in Table 5. There were no
signiﬁcant diﬀerences in the summary scores between the
three groups for urinary, bowel, and hormonal scores. The
sexual summary scores showed no signiﬁcant diﬀerences
between patients who underwent a nerve sparing procedure
(Table 6). Average pad usage was 0.31, 0.23, and 0.42 for
RPP, RRP, and RALP, respectively, with average EPIC score
of 90, 92, and 86 for RPP, RRP, and RALP, respectively (rpp
versus rrp P = .33, rpp versus ralp P = .25, rrp versus ralp
P = .09). In patients undergoing nerve sparing procedure,
the average scores for sexual function were 34, 35, and 38 forProstate Cancer 3
Table 1: Patient Characteristics.
Variable RPP (n = 92) RRP (n = 180) RALP (n = 191) P-value
Age Avg. (SD) 61.1(7.6) 61.7(6.8) 60.1(7.3) 0.12
Pre-op PSA (ng/mL) Avg. (SD) 5.64(2.69) 8.89(9.44) 6.67(7.28) 0.001
Gleason score
≤6
No. (%)
26(28.3) 38(21.1) 91(47.6) <0.001
7 45(48.9) 82(45.6) 89(46.6) 0.87
8–10 21(22.8) 60(33.3) 11(5.5) <0.001
Tumor volume (%) Avg. (SD) 17.7(14.4) 18.0(15.8) 14.8(11.8) 0.056
≤10
No. (%)
40(43.5) 80(44.4) 103(53.9) 0.11
10.1 to 20 24(26.1) 44(24.4) 62(32.5) 0.21
20.1 to 30 14(15.2) 29(16.1) 27(14.1) 0.87
>30 14(15.2) 27(15) 15(7.9) 0.064
Risk classiﬁcation
Low
No. (%)
24(26.1) 37(20.6) 85(44.5) <0.001
Intermediate 47(44.6) 83(46.1) 93(48.7) 0.73
High 21(22.8) 59(32.8) 13(6.8) <0.001
Pathological stage
T2
No. (%)
71(77.2) 131(72.8) 172(90) <0.001
pT2a 18(19.6) 19(10.6) 27(0.14) 0.12
pT2b 2(2.2) 3(1.7) 5(2.6) 0.82
pT2c 51(55.4) 109(60.6) 140(73.3) 0.004
≥pT3a 21(22.8) 49(27.2) 19(9.9) <0.001
EBL (mL) Avg. 475 999.1 189.2 <0.001
Length of stay (days) Avg. 1.29 2.28 1.23 <0.001
Table 2: PSM incidence based on % tumor volume among RPP, RRP, and RALP.
Tumor volume (%) RPP
(n = 21)
RRP
(n = 52)
RALP
(n = 26) P-value
Less than 20
No. (%)
13(61.9) 26 (50) 13 (50) 0.63
20.1 to 30 3 (14.3) 13 (25) 6 (23.1) 0.62
Greater than 30 6 (28.6) 13 (25) 7 (26.9) 0.95
Table 3: PSM incidence based on risk classiﬁcation among RPP, RRP, and RALP.
Risk classiﬁcation RPP
(n = 21)
RRP
(n = 52)
RALP
(n = 26) P-value
Low
No. (%)
2(9.5) 6(11.5) 5(19.2) 0.56
Intermediate 12(57.1) 20(38.4) 17(65.4) 0.06
High 7(33.3) 26(50) 4(15.4) 0.01
Table 4: Incidence of PSM by location among RPP, RRP, and RALP.
Location RPP
(n = 21)
RRP
(n = 52)
RALP
(n = 26) P-value
Anterior
No. (%)
6(28.6) 9(17.3) 1(3.8) 0.07
Apex 4(19) 9(17.3) 5(19.2) 0.97
Bladder neck 6(28.6) 9(17.3) 2(7.7) 0.17
Posterolateral 6(28.6) 34(65.4) 20(76.9) 0.0034 Prostate Cancer
Table 5: Mean EPIC scores for urinary, bowel, hormonal parameters for RPP, RRP, and RALP.
Parameter RPP RRP RALP P-values
N = 35 N = 46 N = 96 rpp versus rrp rpp versus ralp rrp versus ralp
Urinary summary 88 86 83 0.24 0.24 0.10
Bowel summary 91 94 94 0.18 0.07 0.31
Hormonal summary 88 88 89 0.45 0.40 0.44
Pad usage 90 92 86 0.33 0.25 0.09
Table 6: Mean EPIC scores for sexual parameters for nerve sparing RPP, RRP, and RALP.
Parameter RPP RRP RALP P-values
N = 14 N = 33 N = 78 rpp versus rrp rpp versus ralp rrp versus ralp
Sexual summary 39 43 44 0.32 0.27 0.41
Sexual function 34 35 38 0.43 0.26 0.25
Quality of erection 50 57 60 0.28 0.19 0.36
the RPP, RRP, and RALP groups, respectively, (rpp versus rrp
P = .42, rpp versus ralp P = .26, rrp versus ralp P = .25).
The average quality of erection scores in patient undergoing
nerve spare procedure was 50, 57, and 60 for RPP, RRP, and
RALP, respectively, (rpp versus rrp P = .28, rpp versus ralp
P = .19, rrp versus ralp P = .36).
4. Discussion
In the present study, the PSM incidence was studied among
RPP, RRP, and RALP surgical techniques in the treatment
of clinically localized prostate cancer. All procedures were
performed by a single surgeon (JBT) while pathological
specimens were reviewed by a single pathologist at our
institution (OWT).
Tumors were stratiﬁed into low-, intermediate-, and
high-risk categories based on the classiﬁcation system out-
lined in 2007 AUA Guidelines [13]. Low-risk patients were
more likely to undergo RALP, intermediate-risk RPP, and
high-risk RRP, though these ﬁndings were not statistically
signiﬁcant. As expected, a higher PSM incidence was seen
with increasing risk stratiﬁcation for each group. When
PSM incidence was analyzed for each risk classiﬁcation,
a statistically signiﬁcant increased incidence was seen in
high-risk patients but not for low and intermediate risk
patients. Those undergoing RALP were less likely to have
PSM. This conclusion supports the ﬁndings of 2 other
studies comparing RALP and RRP. Ahlering and Laurila
demonstrated no advantage in PSM rates between RRP and
RALP in low- and intermediate-risk patients [7, 8]. Both of
these studies were also single surgeon—a design which we
believe strengthens their conclusions.
In contrast, studies by Smith and Tewari found decreased
incidence of PSM in RALP patients compared to RRP [5, 6].
However, these conclusions were reached after analyzing
results compiled from multiple surgeons. This raises the
question of potential biases that are invariably introduced
when more than one surgeon’s outcomes are analyzed.
Speciﬁcally, surgical skill and training as well as patient and
technique selection may have impacted results.
In our series, the potential impact of tumor volume
on PSM rates among RPP, RRP, and RALP was studied.
Chun et al. demonstrated that tumor volume is the most
accurate univariate indicator of PSM [14]. Tumor volume is
an important factor to consider when comparing PSM rates
among surgical techniques as it is not accounted for in risk
stratiﬁcation proﬁles. In the present study, RALP patients
had smaller tumor volumes (14.8%) compared to RPP
(17.7%) and RRP (18.0%) patients (P = .056). However,
whenpercenttumorvolumewasaccountedfor,nodiﬀerence
in PSM was seen.
Pathologic staging showed a statistically signiﬁcant
increased likelihood of pT2 over pT3 disease in both RPP
(77.2%) and RALP (87.7%) compared to RRP (67.2%)
groups(P = .01). However, contrary to the ﬁndings of Smith
and colleagues, there were no diﬀerences in PSM found
among the groups for both pT2 and pT3 disease. These
ﬁndings are in agreement with other studies [7, 15].
Innearlyallstudiestodate,theapexisthemostcommon
site of tumor involvement in PSM patients [5, 8, 16]. It is
accepted that this is due in large part to the less-deﬁned pro-
static capsule at the apex as well as the diﬃculty in dividing
the apex in the RRP approach. However, the posterolateral
margin was the most common site in our series. This may
be due in part to a technique using sharp dissection of the
apex during RRP rather than using the McDougal clamp
as previously described [17]. We believe this modiﬁcation,
in addition to the improved apical visualization achieved
during RALP, may account for this improvement in these 2
groups. The high proportion of posterolateral site PSM in all
3groupsismostlikelyareﬂectionofthediﬃcultyindividing
the prostatic pedicle while preserving the neurovascular
bundle.Ingeneral,theRPPapproachgrantsimprovedaccess
to the apex, though at the expense of anterior prostateProstate Cancer 5
exposure. Wieder reported the anterior prostate to be the
most likely site of PSM in RPP [18]. Our series did ﬁnd a
greater likelihood of anterior PSM in the RPP group (28.6%)
versus RRP (17.3%) and RALP (3.8%) groups (P = 0.07).
However, the incidence of PSM at the posterolateral margin
was equal to that of the anterior margin within the RPP
group.
Since the popularity of RRP in the early 1980’s and the
more recent RALP, RPP has seen a decrease in number of
procedures performed. However, it has consistently demon-
strated similar oncologic outcomes to RRP [3, 19, 20]. In our
series, the overall PSM rate in the RPP group (21.4%) was
lower than that of the RRP (28.9%) group (P = .007).
Urinary, sexual, bowel, and hormonal quality of life were
not a function of the surgical technique. Median pad usage
12–18 months postoperatively in all groups was 0. Sexual
summary, sexual function, and quality of erection were not
aﬀected by the surgical technique and showed no signiﬁcant
diﬀerence in patients who had undergone nerve sparing
procedures.
At our institution, RPP is the preferred method for rad-
ical prostatectomy in men with a history of signiﬁcant prior
abdominal surgery, renal transplantation, and/or morbid
obesity. As current trends in the surgical management of
clinically localized prostate cancer continue to emphasize
minimally invasive techniques and shorter convalescence,
we believe that RPP will continue to play a signiﬁcant role
in surgical options. Our results demonstrate that RPP is a
valuable tool in the treatment of select men with clinically-
localized prostate cancer.
Our current study has limitations. It is retrospective and
nonrandomized in design. However to date, no randomized
controlled study of the 3 modalities exists. Also, the decision
of which particular surgical modality is reached by both
surgeon as well as the patient, leaving room for possible
bias. Response rate to EPIC questionnaire was a limitation.
Quality of life data were not available at baseline (pre-op)
or immediately post-op. We feel the strength of the study
is that it is a large single-surgeon series with pathology
reviewed by a single pathologist at our institution and the
ﬁrst to incorporate quality of life data in patients undergoing
RPP.
5. Conclusion
In our series, RALPhas a statistically signiﬁcant lower overall
rate of PSM compared to RPP and RRP. PSM also occurs less
frequently in high-risk patients undergoing RALP. Tumor
volume was overall less in the RALP group compared to
RPP and RRP groups. When PSM incidence is compared
among the groups based on tumor volume, no statistically
signiﬁcant diﬀerence in PSM incidence is observed. Quality
of life outcomes are not aﬀected by which surgical technique
is employed. RPP continues to remain a proven eﬀective
alternative to RRP that oﬀers similar oncologic outcomes
with the beneﬁts associated with a minimally invasive
approach.
References
[1] P. C. Walsh, H. Lepor, and J. C. Eggleston, “Radical prostate-
ctomy with preservation of sexual function: anatomical and
pathological considerations,” Prostate, vol. 4, no. 5, pp. 473–
485, 1983.
[2] J. M. Holzbeierlein, P. Langenstroer, H. J. Porter II, and J.
B. Thrasher, “Case selection and outcome of radical perineal
prostatectomy in localized prostate cancer,” International
Brazilian Journal of Urology, vol. 29, no. 4, pp. 291–299, 2003.
[3] M. J. Harris and C. E. Iselin, “Radical perineal prostatectomy:
cost eﬃcient, outcome eﬀective, minimally invasive prostate
cancer management,” European Urology,v o l .4 4 ,n o .3 ,p p .
303–308, 2003.
[4] S. B. Bhayani, C. P. Pavlovich, T. S. Hsu, W. Sullivan, and L.-
M. Su, “Prospective comparison of short-term convalescence:
laparoscopicradicalprostatectomyversusopenradicalretrop-
ubicprostatectomy,”Urology,vol.61,no.3,pp.612–616,2003.
[ 5 ]J .A .S m i t hJ r . ,R .C .C h a n ,S .S .C h a n ge ta l . ,“ Ac o m p a r i s o n
of the incidence and location of positive surgical margins in
robotic assisted laparoscopic radical prostatectomy and open
retropubic radical prostatectomy,” Journal of Urology, vol. 178,
no. 6, pp. 2385–2390, 2007.
[6] A. Tewari, A. Srivasatava, and M. Menon, “A prospective
comparison of radical retropubic and robot-assisted prostate-
ctomy: experience in one institution,” BJU International, vol.
92, no. 3, pp. 205–210, 2003.
[7] T. E. Ahlering, D. Woo, L. Eichel, D. I. Lee, R. Edwards,
and D. W. Skarecky, “Robot-assisted versus open radical
prostatectomy: a comparison of one surgeon’s outcomes,”
Urology, vol. 63, no. 5, pp. 819–822, 2004.
[8] T. A. J. Laurila, W. Huang, and D. F. Jarrard, “Robotic-assisted
laparoscopic and radical retropubic prostatectomy generate
similar positive margin rates in low and intermediate risk
patients,” Urologic Oncology, vol. 27, no. 5, pp. 529–533, 2009.
[9] J. T. Wei, R. L. Dunn, M. S. Litwin, H. M. Sandler, and
M. G. Sanda, “Development and validation of the Expanded
Prostate Cancer Index Composite (EPIC) for comprehensive
assessment of health-related quality of life in men with
prostate cancer,” Urology, vol. 56, no. 6, pp. 899–905, 2000.
[10] V. R. Patel, R. Thaly, and K. Shah, “Robotic radical prostate-
ctomy: outcomes of 500 cases,” BJU International, vol. 99, no.
5, pp. 1109–1112, 2007.
[11] E.A.Klein,F.Jhaveri,andM.Licht,“Contemporarytechnique
of radical prostatectomy,” in Management of Prostate Cancer,
E. A. Klein, Ed., Humana Press, Totowa, NJ, USA, 2000.
[12] L. H. Sobin and C. E. Wittekind, TNM Classiﬁcation of
Malignant Tumors, John Wiley & Sons, New York, NY, USA,
5th edition, 1997.
[13] A. V. D’Amico, R. Whittington, S. B. Malkowicz et al.,
“Biochemical outcome after radical prostatectomy, external
beam radiation therapy, or interstitial radiation therapy for
clinically localized prostate cancer,” Journal of the American
Medical Association, vol. 280, no. 11, pp. 969–974, 1998.
[14] F. K.-H. Chun, A. Briganti, C. Jeldres et al., “Tumour volume
and high grade tumour volume are the best predictors of
pathologic stage and biochemical recurrence after radical
prostatectomy,” European Journal of Cancer, vol. 43, no. 3, pp.
536–543, 2007.
[15] R. S. Boris, S. A. Kaul, R. C. Sarle, and H. J. Stricker, “Radical
prostatectomy: a single surgeon comparison of retropubic,
perineal, and robotic approaches,” The Canadian Journal of
Urology, vol. 14, no. 3, pp. 3566–3570, 2007.6 Prostate Cancer
[16] M. L. Blute, D. G. Bostwick, E. J. Bergstralh et al., “Anatomic
site-speciﬁc positive margins in organ-conﬁned prostate can-
cer and its impact on outcome after radical prostatectomy,”
Urology, vol. 50, no. 5, pp. 733–739, 1997.
[17] P. C. Walsh, H. Lepor, and J. C. Eggleston, “Radical prostate-
ctomy with preservation of sexual function: anatomical and
pathological considerations,” Prostate, vol. 4, no. 5, pp. 473–
485, 1983.
[18] J. A. Wieder and M. S. Soloway, “Incidence, etiology, location,
prevention and treatment of positive surgical margins after
radical prostatectomy for prostate cancer,” Journal of Urology,
vol. 160, no. 2, pp. 299–315, 1998.
[19] D. M. Janoﬀ and R. O. Parra, “Contemporary appraisal of
radical perineal prostatectomy,” Journal of Urology, vol. 173,
no. 6, pp. 1863–1870, 2005.
[20] R. S. Lance, P. A. Freidrichs, C. Kane et al., “A comparison
of radical retropubic with perineal prostatectomy for local-
ized prostate cancer within the Uniformed Services Urology
Research Group,” BJU International, vol. 87, no. 1, pp. 61–65,
2001.